Hormonal
High-dose GLP-1 receptor agonists (semaglutide 2.4 mg and tirzepatide 15 mg) produce substantial, clinically significant weight loss in adults with obesity, with tirzepatide demonstrating superior efficacy compared to other agents.
If you have obesity, high-dose GLP-1 medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective for weight loss than lifestyle changes alone. Tirzepatide showed the highest efficacy in this review. These treatments work by targeting hormonal pathways that regulate hunger and satiety, and they are most effective when combined with standard lifestyle counseling.
In participants without T2DM, semaglutide 2.4 mg (−14.9% body weight at 68 weeks) and tirzepatide 15 mg (−20.9% at 72 weeks) produced the most substantial effects... Tirzepatide 15 mg was associated with the most weight loss, followed by tirzepatide 10 mg.
Why this rating
Based on a systematic review of 22 phase 3/4 RCTs involving 41,757 participants.
Source
Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review
Jena Velji-Ibrahim et al. · Journal of Obesity · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →